Innate Pharma
Business Services · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
117 Avenue De Luminy Bp 30191, Marseille...Phone Number
+33430303030Website
www.innate-pharma.comRevenue
<$5 MillionStock Symbol
IPHAIndustry
About Innate Pharma
Is Innate Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Innate Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Innate Pharma had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Innate Pharma has new funding data
Congratulate Masked Content for being promoted to Masked Content at Innate Pharma
Product Launch: Get notified when Innate Pharma launches new products
Earning: See what the market has to say on Innate Pharma recently announced quarterly report
Check if Innate Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if Innate Pharma is spiking on competitors!
Recommended Actions
Find VP level buyers at Innate Pharma
Find 3 more new buyers
Company Profile Activity
Activity Insights
Innate Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Innate Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Innate Pharma.
Innate Pharma financials insights
Gather financial insights about Innate Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Series A
$4.4M
Series B
$24.4M
Other Financing Round
$20M
Series C
$16.9M
Share Placement
$22.9M
Share Placement
$56.3M
Debt
$32.5M
Stock/Share Issuance
$34.7M
Innate Pharma Tech Stack
Most Recent Scoops
Innate Pharma News & Media
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement August 14, 2026 8:00 AM EDTCompany...Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call Transcript
Innate Pharma S.A. (IPHA) Q1 2026 Earnings Call May 13, 2026 7:30 AM EDTCompany ParticipantsStephanie Cornen - Vice President of Investor Relations,...Innate Pharma (Nasdaq: IPHA) details Q1 2026 cash runway and trial plans - Stock Titan
Innate Pharma reports €25.4m cash with runway to end Q3 2026, €2.6m Q1 revenue, and key 2026 milestones for lacutamab, IPH4502, and AstraZeneca-partnered lung cancer trials.Innate's NK cell engager is latest victim of pipeline refocus - Fierce Biotech
Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline. | Innate Pharma has finally called time on an NK cell engager in phase 1/2 development as part of an ongoing fine-tuning of the French biotech’s pipeline.
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Innate Pharma
Founded in 1999, Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.... Read More